Acticor Biotech is a biopharmaceutical company developing an antithrombotic agent for the treatment of the acute phase of ischemic stroke. Acticor Biotech is a spin-off company from Inserm (French National Institute of Health and Medical Research) founded in November 2013 and located in the Inserm U1148 building inside the Bichat Hospital in Paris. Acticor Biotech develops a biologic drug candidate based on academic research on a platelet glycoprotein called GPVI. GPVI is a platelet receptor of collagen and polymerized fibrin. The drug candidate ACT017 is a humanized fragment of monoclonal antibody which binds to GPVI and inhibits platelet adhesion and aggregation on collagen and polymerized fibrin.
Bichat Hospital - INSERM U1148 46, Henri Huchard Street 75018 PARIS
Others
Acticor Biotech is a biopharmaceutical company developing an antithrombotic agent for the treatment of the acute phase of ischemic stroke.
Acticor Biotech is a spin-off company from Inserm (French National Institute of Health and Medical Research) founded in November 2013 and located in the Inserm U1148 building inside the Bichat Hospital in Paris.
Acticor Biotech develops a biologic drug candidate based on academic research on a platelet glycoprotein called GPVI. GPVI is a platelet receptor of collagen and polymerized fibrin. The drug candidate ACT017 is a humanized fragment of monoclonal antibody which binds to GPVI and inhibits platelet adhesion and aggregation on collagen and polymerized fibrin.
Market Place
